Aquestive Therapeutics, Inc. - SIC # 6710 -

Ticker Exchange SIC # Website Latest Ticker
AQST Nasdaq 6710 www.aquestive.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aquestive Therapeutics, Inc.

Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last? - Jun 24th, 2026 5:32 am
Does US manufacturing give drugmakers a speed edge? - Jun 23rd, 2026 1:00 am
The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts - May 15th, 2026 6:56 am
Aquestive Therapeutics Inc (AQST) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ... - May 14th, 2026 5:03 pm
Aquestive Therapeutics Q1 Earnings Call Highlights - May 14th, 2026 8:07 am
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics - May 13th, 2026 4:00 pm
Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates - May 13th, 2026 3:15 pm
12 Health Care Stocks Moving In Wednesday's After-Market Session - May 13th, 2026 3:06 pm
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - May 13th, 2026 2:01 pm
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree - May 12th, 2026 7:31 am
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates - May 7th, 2026 3:55 pm
Will Journey Medical Corporation (DERM) Report Negative Q1 Earnings? What You Should Know - May 6th, 2026 8:00 am
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET - May 6th, 2026 5:00 am
Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should Know - May 4th, 2026 8:00 am
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Apr 9th, 2026 7:00 am
Aquestive Therapeutics (AQST) Awaits Anaphylm NDA Approval in Q3 - Mar 31st, 2026 5:34 am
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film - Mar 30th, 2026 5:00 am
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer - Mar 20th, 2026 5:00 am
Aquestive Therapeutics Targets Q3 Anaphylm Resubmission After FDA CRL Flags Human Factors, PK Data - Mar 11th, 2026 12:04 am
Aquestive Therapeutics Targets Q3 Anaphylm FDA Resubmission After CRL, Details Launch Plans at Leerink Conf - Mar 10th, 2026 12:02 am